Amgen falls after obesity study results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/11/2026
- Wall Street ends higher as investors turn to earnings season
- Oil prices settle lower on hopes for smoother shipping in Strait of Hormuz
- The real reason Meta shares are surging has nothing to do with its new AI model
- Stifel lifts Shopify to Buy, sees agentic commerce as next growth catalyst
- Delta Air Lines stock climbs on earnings beat and strong guidance
- Almonty Industries (ALM) PT Raised to $33 at DA Davidson
- JPMorgan analysts name top short ideas for third quarter 2026
- The real reason Meta shares are surging has nothing to do with its new AI model
- AppLovin gains market share among e-commerce advertisers
- Wall Street ends higher as investors turn to earnings season
Amgen (AMGN) PT Raised to $352 at Leerink Partners
November 27, 2024 6:19 AM ESTLeerink Partners analyst David Risinger raised the price target on Amgen (NASDAQ: AMGN) to $352.00 (from $305.00) while maintaining a Market Perform rating.
The analyst comments "Bottom Line: We are lowering our PT from $352 (18x 2025E EPS of $19.55) to $305 (15x 2025E EPS of $20.33) and maintaining our Market Perform rating. We lowered our 5- yr (25-30) CAGR EPS from 8% to 4%, largely driven by higher investment spending assumptions. MariTides Ph2 results... More
Piper Sandler Reiterates Overweight Rating on Amgen (AMGN)
November 26, 2024 10:37 AM ESTPiper Sandler analyst Christopher Raymond reiterated an Overweight rating and $344.00 price target on Amgen (NASDAQ: AMGN).
The analyst comments "Remain OW rated on AMGN shares and would expect the stock to eventually recover from todays initial sell-off on AMGNs... More
